The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...

The sequence of the wild type G gene was refractory to cloning into full-length antigenomic cDNA in E. coli, and so the inventors made and successfully used a codon optimized version. In addition ...

Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal ...

GenScript’s DNA synthesis process employs on-site sequence optimization and oligo design, followed by oligo synthesis and gene assembly. The unique GenSmart TM Codon Optimization tool ...

The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.

Viralgen and Axovia Therapeutics are joining forces to advance the development and manufacture of an AAV9-based inv ...